temanogrel hydrochloride (APD-791) / Ildong, Pfizer - LARVOL DELTA

Pfizer Cuts Mid-Stage Candidates Amid Declining Revenues (BioSpace) - "Fresh off its $43 billion acquisition of Seagen, Pfizer is making deep cuts to its Phase II pipeline in cardiology and inflammatory diseases, the company revealed Tuesday during its first-quarter financial report. On Pfizer’s chopping block is temanogrel, an inverse agonist of the serotonin 2A receptor being trialed for microvascular obstruction and Raynaud’s phenomenon related to systemic sclerosis. Pfizer is also dumping its cardio candidate APD418, an antagonist of the beta-3 adrenergic receptor in Phase II studies for acute heart failure...Pfizer’s pipeline clean-out also included the biologic blocker of the TNFSF15 protein for ulcerative colitis and the CXCR2 antagonist RIST4721, which was in Phase II studies for hidradenitis suppurativa and palmoplantar pustulosis."

Pipeline update • Cardiovascular • Heart Failure • Hidradenitis Suppurativa • Immunology • Myocardial Ischemia

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention (clinicaltrials.gov) - P2 | N=29 | Terminated | Sponsor: Arena Pharmaceuticals | N=99 ➔ 29 | Recruiting ➔ Terminated; Business decision

Enrollment change • Trial termination

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention (clinicaltrials.gov) - P2 | N=99 | Recruiting | Sponsor: Arena Pharmaceuticals | Trial completion date: Apr 2022 ➔ Sep 2022 | Trial primary completion date: Apr 2022 ➔ Sep 2022

Trial completion date • Trial primary completion date

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention (clinicaltrials.gov) - P2; N=99; Recruiting; Sponsor: Arena Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open